This study is investigating a treatment for locoregional hepatocellular carcinoma (HCC), a type of liver cancer that hasn't spread widely. Researchers want to see if adding the medicines durvalumab, tremelimumab, and lenvatinib to a procedure called transarterial chemoembolization (TACE) works better than TACE alone. TACE is a treatment that delivers chemotherapy directly to the liver cancer. This study is Phase III, meaning it's advanced and involves many participants worldwide.

To join, you must have a certain stage of liver disease (Child Pugh score class A) and be physically able to perform daily activities (ECOG performance status 0 or 1). Your cancer should be measurable and not suitable for surgery or other curative treatments. There are also conditions that would exclude you, like certain heart problems or liver diseases.

• The study involves different treatment groups and is conducted at multiple international locations.
• Participants will receive either a combination of medicines with TACE or TACE alone.
• This study aims to find a safer and more effective treatment for liver cancer.